FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667041> ?p ?o ?g. }

• W4385667041 endingPage "e20461da" @default.
• W4385667041 startingPage "e20461da" @default.
• W4385667041 abstract "Topic: 16. Myeloproliferative neoplasms - Clinical Background: Langerhans cell histiocytosis (LCH) is a rare, heterogeneous histiocytic disorder occurring in patients of all ages from neonates to the elderly. The features of LCH are well described in children, however, they remain poorly defined in adults. There is no standard first-line treatment for adult LCH. A previous study at our institution showed that methotrexate combined with a low dose cytarabine regimen was effective but with high hematologic toxicity. Aims: This study was designed to evaluate the efficacy and safety of a low dose cytarabine regimen treatment in adults. Methods: This phase 2, prospective, single-center study enrolled 59 newly diagnosed adults multisystem (MS)-LCH or LCH with multifocal single system (SS-m) involved from October 2019 to January 2022 (NCT 04121819). The low dose cytarabine regimen was injected subcutaneously as cytarabine 0.1g/m2 (body surface) day 1-5 every 5 weeks for a cycle and 12 cycles in total. The primary endpoint was event-free survival (EFS). Events were defined as a poor response to chemotherapy, reactivation after chemotherapy or death from any cause. Results: The median age was 33 years (range 18-64 years). Thirty-nine patients were male (66.1%). Thirteen patients were SS-m LCH (22.0%), and 46 patients were MS LCH (78.0%). The most common organ involved in the total cohort was bone (74.6%), followed by lung (50.8%), pituitary (40.7%) and lymph nodes (27.1%). Thirteen patients had liver involvement (22.0%), 2 patients with spleen involvement (3.4%), no patients had hematologic involvement. All patients received at least three courses of chemotherapy, with median 12 (3-12) courses. Overall, 43 patients (72.9%) completed protocol treatment, and 16 patients (27.1%) went off protocol (9 patients’ decision, 5 poor response, 1 lost follow-up, 1 death). The overall response rate was 89.8%, including 15 patients (25.4%) achieving complete remission and 38 patients (64.4%) achieving partial remission. After a median follow-up of 25 months (range 3-41 months), 2 (3.4%) patients died of progression disease and 14 (23.7%) patients relapsed. The estimated 2-year OS and EFS were 98.3% and 73.0%, respectively. To evaluate the prognostic factors of EFS using univariate analysis, lung involvement and 3 or more organs involved at baseline had significantly shorter EFS. EFS were also evaluated using multivariate Cox regression model, lung involvement remained predictive of poorer EFS (P = 0.036; HR 0.247, 95% CI 0.066–0.915). The most common toxicity was hematological adverse events and gastrointestinal complications. 33 patients (55.9%) experienced neutropenia or thrombocytopenia. 7 patients (11.9%) had grade 4 neutropenia; 8 patients (13.6%) had grade 3 neutropenia. Only 1 patient (1.7%) had grade 4 thrombocytopenia; No patients experienced febrile neutropenia. 33 patients (55.9%) developed nausea, and 1 of them were grade 3. Vomiting occurred in 16 patients (27.1%) and constipation in 1 patient (1.7%), and none of them was grade 3-4. All gastrointestinal complications improved with supportive treatment. Alanine aminotransferase increases occurred in 6 patients (10.2%) with grade 1-2 events. and achieved a full recovery. Summary/Conclusion: Low dose cytarabine regimen is an efficient and safe regimen for newly diagnosed adult LCH. The involvement of lung at baseline indicates a worse prognosis in adult LCH.Keywords: Langerhans Cell Histiocytosis, Chemotherapy" @default.
• W4385667041 created "2023-08-09" @default.
• W4385667041 creator A5039857961 @default.
• W4385667041 creator A5045814990 @default.
• W4385667041 creator A5047258498 @default.
• W4385667041 creator A5049314514 @default.
• W4385667041 creator A5055407864 @default.
• W4385667041 creator A5089902877 @default.
• W4385667041 date "2023-08-01" @default.
• W4385667041 modified "2023-10-14" @default.
• W4385667041 title "P1039: LOW DOSE CYTARABINE FOR ADULT PATIENTS WITH NEWLY DIAGNOSED LANGERHANS CELL HISTIOCYTOSIS: A SINGLE ARM, SINGLE CENTER, PROSPECTIVE PHASE 2 STUDY" @default.
• W4385667041 doi "https://doi.org/10.1097/01.hs9.0000971052.20461.da" @default.
• W4385667041 hasPublicationYear "2023" @default.
• W4385667041 type Work @default.
• W4385667041 citedByCount "0" @default.
• W4385667041 crossrefType "journal-article" @default.
• W4385667041 hasAuthorship W4385667041A5039857961 @default.
• W4385667041 hasAuthorship W4385667041A5045814990 @default.
• W4385667041 hasAuthorship W4385667041A5047258498 @default.
• W4385667041 hasAuthorship W4385667041A5049314514 @default.
• W4385667041 hasAuthorship W4385667041A5055407864 @default.
• W4385667041 hasAuthorship W4385667041A5089902877 @default.
• W4385667041 hasBestOaLocation W43856670411 @default.
• W4385667041 hasConcept C126322002 @default.
• W4385667041 hasConcept C141071460 @default.
• W4385667041 hasConcept C188816634 @default.
• W4385667041 hasConcept C2776694085 @default.
• W4385667041 hasConcept C2777484599 @default.
• W4385667041 hasConcept C2778041864 @default.
• W4385667041 hasConcept C2779134260 @default.
• W4385667041 hasConcept C2780073493 @default.
• W4385667041 hasConcept C2781413609 @default.
• W4385667041 hasConcept C71924100 @default.
• W4385667041 hasConcept C90924648 @default.
• W4385667041 hasConceptScore W4385667041C126322002 @default.
• W4385667041 hasConceptScore W4385667041C141071460 @default.
• W4385667041 hasConceptScore W4385667041C188816634 @default.
• W4385667041 hasConceptScore W4385667041C2776694085 @default.
• W4385667041 hasConceptScore W4385667041C2777484599 @default.
• W4385667041 hasConceptScore W4385667041C2778041864 @default.
• W4385667041 hasConceptScore W4385667041C2779134260 @default.
• W4385667041 hasConceptScore W4385667041C2780073493 @default.
• W4385667041 hasConceptScore W4385667041C2781413609 @default.
• W4385667041 hasConceptScore W4385667041C71924100 @default.
• W4385667041 hasConceptScore W4385667041C90924648 @default.
• W4385667041 hasIssue "S3" @default.
• W4385667041 hasLocation W43856670411 @default.
• W4385667041 hasLocation W43856670412 @default.
• W4385667041 hasOpenAccess W4385667041 @default.
• W4385667041 hasPrimaryLocation W43856670411 @default.
• W4385667041 hasRelatedWork W2003938723 @default.
• W4385667041 hasRelatedWork W2047967234 @default.
• W4385667041 hasRelatedWork W2118496982 @default.
• W4385667041 hasRelatedWork W2364998975 @default.
• W4385667041 hasRelatedWork W2439875401 @default.
• W4385667041 hasRelatedWork W3024189281 @default.
• W4385667041 hasRelatedWork W3033961351 @default.
• W4385667041 hasRelatedWork W4238867864 @default.
• W4385667041 hasRelatedWork W4386034530 @default.
• W4385667041 hasRelatedWork W2525756941 @default.
• W4385667041 hasVolume "7" @default.
• W4385667041 isParatext "false" @default.
• W4385667041 isRetracted "false" @default.
• W4385667041 workType "article" @default.